Johnson & Johnson (JNJ)

$226.10 -0.06 (-0.03%)
Market Cap 544.73B
Revenue (ttm) 94.19B
Net Income (ttm) 26.80B
EPS (ttm) N/A
PE Ratio 21.50
Forward PE 19.94
Profit Margin 28.46%
Debt to Equity Ratio 0.48
Volume 9,003,300
Avg Vol 8,286,820
Day's Range N/A - N/A
Shares Out 2.41B
Stochastic %K 13%
Beta 0.34
Analysts Strong Sell
Price Target $254.72

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 732 524 0400
Website: www.jnj.com
Address:
One Johnson & Johnson Plaza, New Brunswick, United States
dosaman
dosaman Apr. 22 at 11:10 PM
$JNJ tech sell off needed for safe havens like JNJ, AMGN, MRK, LLY to head higher. All in consolidation mode.
0 · Reply
Quantumup
Quantumup Apr. 22 at 8:47 PM
Morgan Stanley⬆️(a/o 4/19) $ABVX and said: Abivax (ABVX, OW, $110 to $170 Base Case Range, Current Price ~$120), Approaching Ph3 Maintenance Data in UC: $JNJ - $PTGX TEVA ROIV - RHHBY SYRE ABBV TAK PFE BMY LLY Here's what else Morgan Stanley had to say: https://x.com/Quantumup1/status/2047053518503092554?s=20
0 · Reply
TechTraderGrok
TechTraderGrok Apr. 22 at 8:00 PM
Bought $JNJ at $225.34. From Grok: "JNJ has sold off sharply to 224.58 amid litigation worries and Stelara biosimilar pressure, but strong Q1 results, raised 2026 guidance, and repeated analyst price target hikes to $250–$280 make this an attractive entry for a rebound.[[1]](https://www.investor.jnj.com/investor-news/news-details/2026/Johnson--Johnson-reports-Q1-2026-results-raises-2026-outlook/default.aspx)" https://www.techtrader.ai/grokwall/?post=17837&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
G101SPM
G101SPM Apr. 22 at 6:39 PM
#SHOWTIME Pfizer Inc. Annual General Meeting (April 23) Scheduled to appear: $PFE Johnson & Johnson Annual General Meeting (April 23) Scheduled to appear: $JNJ HCA Healthcare Inc Annual General Meeting (April 23) Scheduled to appear:$ HCA
0 · Reply
focafoca99
focafoca99 Apr. 22 at 6:37 PM
$JNJ IMAAVY showed more than two years of sustained disease control in generalized myasthenia gravis. https://www.rapidticker.com/news/jnj-imaavy-nipocalimab-aahu-shows-over-210c35
0 · Reply
JCH007
JCH007 Apr. 22 at 6:26 PM
$JNJ Guess it's blue light special day here at the JNJ. Who don't love a bargain. I'm in!
0 · Reply
ElliottwaveForecast
ElliottwaveForecast Apr. 22 at 5:01 PM
$JNJ has pulled back into the 227.8 – 215.8 zone, a key area where buyers could step in and drive the stock back toward its All-Time Highs. Read more 👉https://elliottwave-forecast.com/stock-market/jnj-forecast-buyers-should-enter-227-8-215-8-area/ #Trading #Elliottwave
0 · Reply
Suite510
Suite510 Apr. 22 at 3:54 PM
$JNJ $ABT Like i said before both have major baby issues 🤣 Critical Mass With http://Law.com’s Amanda Bronstad: 13 Lawyers Line Up to Lead Talc MDL’s Next Phase! here comes the bus 🚃
0 · Reply
bbq1232
bbq1232 Apr. 22 at 3:53 PM
$JNJ so is there a reason for the cliff dive today or just normal kangaroo market?
0 · Reply
JCH007
JCH007 Apr. 22 at 3:32 PM
$JNJ Yeah...this decline makes sense. Not!
0 · Reply
Latest News on JNJ
IMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG)

Apr 22, 2026, 8:05 AM EDT - 15 hours ago

IMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG)

Johnson & Johnson Announces CE Mark Approval for the New ETHICON™ 4000 Stapler

Apr 22, 2026, 4:00 AM EDT - 19 hours ago

Johnson & Johnson Announces CE Mark Approval for the New ETHICON™ 4000 Stapler

Johnson & Johnson to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

Apr 21, 2026, 4:22 PM EDT - 1 day ago

Johnson & Johnson to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

Johnson & Johnson Showcases CARTO-Powered Innovation, Including Debut of CARTOSOUND SONATA, to Advance Arrhythmia Care at HRS 2026

Apr 21, 2026, 7:45 AM EDT - 1 day ago

Johnson & Johnson Showcases CARTO-Powered Innovation, Including Debut of CARTOSOUND SONATA, to Advance Arrhythmia Care at HRS 2026

US judge rejects Bayer bid to block Johnson & Johnson prostate cancer drug claims

Apr 17, 2026, 10:36 PM EDT - 5 days ago

US judge rejects Bayer bid to block Johnson & Johnson prostate cancer drug claims

U.S. judge rejects Bayer's bid to block Johnson & Johnson prostate cancer drug claims

Apr 17, 2026, 7:00 PM EDT - 5 days ago

U.S. judge rejects Bayer's bid to block Johnson & Johnson prostate cancer drug claims

Eli Lilly Partner MeiraGTx Regains Rights For Genetic Eye Disease Drug From Johnson & Johnson

Apr 16, 2026, 10:16 AM EDT - 6 days ago

Eli Lilly Partner MeiraGTx Regains Rights For Genetic Eye Disease Drug From Johnson & Johnson

LLY MGTX

Johnson & Johnson to Participate in the Bank of America 2026 Healthcare Conference

Apr 15, 2026, 4:11 PM EDT - 7 days ago

Johnson & Johnson to Participate in the Bank of America 2026 Healthcare Conference

These Analysts Boost Their Forecasts On Johnson & Johnson Following Strong Q1 Results

Apr 15, 2026, 1:43 PM EDT - 7 days ago

These Analysts Boost Their Forecasts On Johnson & Johnson Following Strong Q1 Results

Johnson & Johnson Posts Solid Q1 To Kickstart 'Year Of Accelerating Growth,' Says Bullish Analyst

Apr 15, 2026, 12:37 PM EDT - 7 days ago

Johnson & Johnson Posts Solid Q1 To Kickstart 'Year Of Accelerating Growth,' Says Bullish Analyst

Johnson & Johnson CFO on the company's robotic surgical system

Apr 14, 2026, 10:51 AM EDT - 8 days ago

Johnson & Johnson CFO on the company's robotic surgical system

Tuesday's Morning Movers: ORCL & BE Extend Partnership, KMX & JNJ Earnings

Apr 14, 2026, 10:30 AM EDT - 8 days ago

Tuesday's Morning Movers: ORCL & BE Extend Partnership, KMX & JNJ Earnings

ORCL BE KMX

J&J raises guidance for 2026 on strong start to the year

Apr 14, 2026, 6:55 AM EDT - 8 days ago

J&J raises guidance for 2026 on strong start to the year

J&J's first-quarter profit beats estimates even as Stelara sales disappoint

Apr 14, 2026, 6:25 AM EDT - 8 days ago

J&J's first-quarter profit beats estimates even as Stelara sales disappoint

Johnson & Johnson Announces 64th Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 3.1%

Apr 14, 2026, 6:21 AM EDT - 8 days ago

Johnson & Johnson Announces 64th Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 3.1%

Johnson & Johnson reports Q1 2026 results, raises 2026 outlook

Apr 14, 2026, 6:20 AM EDT - 8 days ago

Johnson & Johnson reports Q1 2026 results, raises 2026 outlook

J&J's First-Quarter Sales Grow on Cancer-Drug Strength

Apr 14, 2026, 6:20 AM EDT - 8 days ago

J&J's First-Quarter Sales Grow on Cancer-Drug Strength

Dow Jones Stocks In Spotlight: JPMorgan, Johnson & Johnson Among This Week's Earnings Reports

Apr 13, 2026, 11:36 AM EDT - 9 days ago

Dow Jones Stocks In Spotlight: JPMorgan, Johnson & Johnson Among This Week's Earnings Reports

JPM DIA TRV

Goldman Sachs, Bank of America, JP Morgan, Netflix, J&J, Producer Prices, and More to Watch This Week

Apr 12, 2026, 2:00 PM EDT - 10 days ago

Goldman Sachs, Bank of America, JP Morgan, Netflix, J&J, Producer Prices, and More to Watch This Week

NFLX BAC GS JPM

Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of Vision

Apr 10, 2026, 8:00 AM EDT - 12 days ago

Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of Vision

Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Apr 9, 2026, 7:57 AM EDT - 13 days ago

Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Buy Johnson & Johnson Ahead of Earnings. The Stock's Run-Up Isn't Over.

Apr 8, 2026, 10:41 AM EDT - 14 days ago

Buy Johnson & Johnson Ahead of Earnings. The Stock's Run-Up Isn't Over.

Johnson & Johnson Advances Pulsed Field Ablation Portfolio with the Launch of VARIPULSE Pro in Europe

Apr 7, 2026, 8:00 AM EDT - 15 days ago

Johnson & Johnson Advances Pulsed Field Ablation Portfolio with the Launch of VARIPULSE Pro in Europe

Royalty Pharma and J&J partner to develop autoimmune treatment

Mar 30, 2026, 9:14 AM EDT - 23 days ago

Royalty Pharma and J&J partner to develop autoimmune treatment

RPRX

ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis

Mar 28, 2026, 10:00 AM EDT - 25 days ago

ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis

Johnson & Johnson (JNJ) Price Forecast: Bull Flag Signals Strength

Mar 27, 2026, 4:46 PM EDT - 26 days ago

Johnson & Johnson (JNJ) Price Forecast: Bull Flag Signals Strength

Johnson & Johnson's DARZALEX® (daratumumab) becomes the first oncology injectable approved for administration by patients or caregivers

Mar 27, 2026, 6:31 AM EDT - 26 days ago

Johnson & Johnson's DARZALEX® (daratumumab) becomes the first oncology injectable approved for administration by patients or caregivers

The Big 3: ORCL, JNJ, SBUX

Mar 19, 2026, 1:00 PM EDT - 4 weeks ago

The Big 3: ORCL, JNJ, SBUX

ORCL SBUX

JNJ Stock's Re-Rating: When The Market Finally Sees A Different Company

Mar 19, 2026, 9:35 AM EDT - 4 weeks ago

JNJ Stock's Re-Rating: When The Market Finally Sees A Different Company

TrumpRx lists many medicines at prices higher than paid in UK

Mar 18, 2026, 2:23 PM EDT - 5 weeks ago

TrumpRx lists many medicines at prices higher than paid in UK

ABBV AMGN AZN BMY GILD GSK LLY

FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi

Mar 18, 2026, 1:17 PM EDT - 5 weeks ago

FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi

US FDA approves J&J's oral psoriasis pill

Mar 18, 2026, 8:31 AM EDT - 5 weeks ago

US FDA approves J&J's oral psoriasis pill

FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide

Mar 18, 2026, 7:49 AM EDT - 5 weeks ago

FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide

Johnson & Johnson Drives Innovation in Pulsed Field Ablation with Peru Launch

Mar 16, 2026, 11:00 AM EDT - 5 weeks ago

Johnson & Johnson Drives Innovation in Pulsed Field Ablation with Peru Launch

Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer

Mar 13, 2026, 12:35 PM EDT - 5 weeks ago

Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer

Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients

Mar 12, 2026, 8:00 AM EDT - 5 weeks ago

Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients

Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line

Mar 5, 2026, 3:55 PM EST - 6 weeks ago

Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line

US FDA approves JNJ's blood cancer drug

Mar 5, 2026, 2:21 PM EST - 6 weeks ago

US FDA approves JNJ's blood cancer drug

Johnson & Johnson launches website for direct-to-consumer sales

Mar 4, 2026, 6:07 PM EST - 7 weeks ago

Johnson & Johnson launches website for direct-to-consumer sales

Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE)

Mar 3, 2026, 8:03 AM EST - 7 weeks ago

Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE)

Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

Mar 2, 2026, 4:30 PM EST - 7 weeks ago

Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer

Feb 26, 2026, 2:30 PM EST - 7 weeks ago

Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer

Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA)

Feb 24, 2026, 4:03 PM EST - 2 months ago

Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA)

Does JNJ Stock Still Offer Value?

Feb 23, 2026, 11:35 AM EST - 2 months ago

Does JNJ Stock Still Offer Value?

Bayer files lawsuit against Johnson & Johnson, Janssen Biotech

Feb 23, 2026, 10:43 AM EST - 2 months ago

Bayer files lawsuit against Johnson & Johnson, Janssen Biotech

Bayer Alleges J&J's Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J's ERLEADA

Feb 23, 2026, 10:28 AM EST - 2 months ago

Bayer Alleges J&J's Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J's ERLEADA

TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years

Feb 21, 2026, 8:00 AM EST - 2 months ago

TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer

Feb 19, 2026, 5:00 PM EST - 2 months ago

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer

Johnson & Johnson explores $20 billion sale of an orthopedics unit, Bloomberg News reports

Feb 19, 2026, 2:34 PM EST - 2 months ago

Johnson & Johnson explores $20 billion sale of an orthopedics unit, Bloomberg News reports

Johnson & Johnson to invest $1B in Pennsylvania manufacturing facility

Feb 19, 2026, 2:11 PM EST - 2 months ago

Johnson & Johnson to invest $1B in Pennsylvania manufacturing facility

dosaman
dosaman Apr. 22 at 11:10 PM
$JNJ tech sell off needed for safe havens like JNJ, AMGN, MRK, LLY to head higher. All in consolidation mode.
0 · Reply
Quantumup
Quantumup Apr. 22 at 8:47 PM
Morgan Stanley⬆️(a/o 4/19) $ABVX and said: Abivax (ABVX, OW, $110 to $170 Base Case Range, Current Price ~$120), Approaching Ph3 Maintenance Data in UC: $JNJ - $PTGX TEVA ROIV - RHHBY SYRE ABBV TAK PFE BMY LLY Here's what else Morgan Stanley had to say: https://x.com/Quantumup1/status/2047053518503092554?s=20
0 · Reply
TechTraderGrok
TechTraderGrok Apr. 22 at 8:00 PM
Bought $JNJ at $225.34. From Grok: "JNJ has sold off sharply to 224.58 amid litigation worries and Stelara biosimilar pressure, but strong Q1 results, raised 2026 guidance, and repeated analyst price target hikes to $250–$280 make this an attractive entry for a rebound.[[1]](https://www.investor.jnj.com/investor-news/news-details/2026/Johnson--Johnson-reports-Q1-2026-results-raises-2026-outlook/default.aspx)" https://www.techtrader.ai/grokwall/?post=17837&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
G101SPM
G101SPM Apr. 22 at 6:39 PM
#SHOWTIME Pfizer Inc. Annual General Meeting (April 23) Scheduled to appear: $PFE Johnson & Johnson Annual General Meeting (April 23) Scheduled to appear: $JNJ HCA Healthcare Inc Annual General Meeting (April 23) Scheduled to appear:$ HCA
0 · Reply
focafoca99
focafoca99 Apr. 22 at 6:37 PM
$JNJ IMAAVY showed more than two years of sustained disease control in generalized myasthenia gravis. https://www.rapidticker.com/news/jnj-imaavy-nipocalimab-aahu-shows-over-210c35
0 · Reply
JCH007
JCH007 Apr. 22 at 6:26 PM
$JNJ Guess it's blue light special day here at the JNJ. Who don't love a bargain. I'm in!
0 · Reply
ElliottwaveForecast
ElliottwaveForecast Apr. 22 at 5:01 PM
$JNJ has pulled back into the 227.8 – 215.8 zone, a key area where buyers could step in and drive the stock back toward its All-Time Highs. Read more 👉https://elliottwave-forecast.com/stock-market/jnj-forecast-buyers-should-enter-227-8-215-8-area/ #Trading #Elliottwave
0 · Reply
Suite510
Suite510 Apr. 22 at 3:54 PM
$JNJ $ABT Like i said before both have major baby issues 🤣 Critical Mass With http://Law.com’s Amanda Bronstad: 13 Lawyers Line Up to Lead Talc MDL’s Next Phase! here comes the bus 🚃
0 · Reply
bbq1232
bbq1232 Apr. 22 at 3:53 PM
$JNJ so is there a reason for the cliff dive today or just normal kangaroo market?
0 · Reply
JCH007
JCH007 Apr. 22 at 3:32 PM
$JNJ Yeah...this decline makes sense. Not!
0 · Reply
prismmarketview
prismmarketview Apr. 22 at 1:42 PM
$JNJ JNJ News Reports Sustained Efficacy of IMAAVY for Generalized Myasthenia Gravis https://prismmarketview.com/imaavy-sustained-disease-control-myasthenia-gravis/
0 · Reply
Bazzzigar
Bazzzigar Apr. 22 at 12:49 PM
$JNJ few more
0 · Reply
DragonAlgo
DragonAlgo Apr. 22 at 9:13 AM
🐉 $JNJ CALL — DragonAlgo® Signal Contract: JNJ CALL Expiry: 2026-04-24 | Strike: $225.00 | Type: CALL Option Plan (premium): Entry: $3.05 Stop: $2.20 TP1: $3.96 TP2: $5.18 TP3: $7.32 Momentum tape remains active. 🔗 https://dragonalgo.com
0 · Reply
ElliottwaveForecast
ElliottwaveForecast Apr. 22 at 8:00 AM
Johnson & Johnson $JNJ Forecast — buyers should look to enter between the 227.8 – 215.8 area. Read the full blog for detailed Elliott Wave setup → https://elliottwave-forecast.com/stock-market/jnj-forecast-buyers-should-enter-227-8-215-8-area/ #Elliottwave #Trading
0 · Reply
Pudgeman007
Pudgeman007 Apr. 21 at 10:56 PM
$JNJ This clown has no website! No bio, track record, selling on an E-commerce site. Hey stocktwits he spammed over 100 tickers in the last hour
0 · Reply
dosaman
dosaman Apr. 21 at 10:31 PM
$JNJ when in doubt look at this. We will bounce back.
0 · Reply
ElliottwaveForecast
ElliottwaveForecast Apr. 21 at 9:38 PM
💊 $JNJ buyers should watch the Blue Box zone at 227.8–215.8 👀 This pullback looks corrective and could offer the next high-probability buying opportunity before the next leg higher resumes 📈 Don’t chase—wait for the right setup and trade with the trend. Read more: https://elliottwave-forecast.com/stock-market/jnj-forecast-buyers-should-enter-227-8-215-8-area/ #JNJ #Elliottwave #Stocks #Trading #Investing
0 · Reply
MHM7700
MHM7700 Apr. 21 at 8:45 PM
$JNJ 05/01 220p $2.02
0 · Reply
SenefAS
SenefAS Apr. 21 at 8:16 PM
$GMAB Genmab a lot of options tonight… Something is cooking 🤔 $NVO $JNJ
1 · Reply
frontiere
frontiere Apr. 21 at 7:16 PM
$JNJ Johnson & Johnson ref=$226 — NO pstn but maybe would short >239 ? Similar to NVS 👇, a multi-year breakout?
0 · Reply
DDaphne52
DDaphne52 Apr. 21 at 6:32 PM
$JNJ breaking down
0 · Reply
deltax10
deltax10 Apr. 21 at 5:13 PM
$JNJ buy 500 shares at 226, since then going down Officially bag holder 🤣🤣🤣
0 · Reply